Abstract
Background: Patients with hepatocellular carcinoma frequently develop portal venous invasion, a diagnosis of which affects patient prognosis. We have already shown the close association between the development of portal venous invasion and serum des-y-carboxy prothrombin levels in patients with hepatocellular carcinoma (Figure 1) [1]. In addition, it has been reported that vitamin K2 administration decreases serum des-y-carboxy prothrombin levels in hepatocellular carcinoma patients and inhibits the proliferation of hepatocellular.
Incidence of Portal Venous Invasion (PVI) after local ablation of hepatocellular carcinoma
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-y-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. Cancer 2001;91:561–569.
Ni R, Nishikawa Y, Can BI. Cell growth inhibition by a novel vitamin K is associated with induction of protein tyrosine phosphorylation. J Biol Chem 1998;273:9906–11.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Japan
About this paper
Cite this paper
Koike, Y., Shiratori, Y., Yoshida, H., Omata, M. (2004). Vitamin K2 Administration Improves the Prognoses of Patients with Hepatocellular Carcinoma Presenting High Levels of Serum Des-γ-Carboxy Prothrombin. In: Omata, M., Okita, K. (eds) Therapy for Viral Hepatitis and Prevention of Hepatocellular Carcinoma. Springer, Tokyo. https://doi.org/10.1007/978-4-431-53977-3_24
Download citation
DOI: https://doi.org/10.1007/978-4-431-53977-3_24
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-67975-2
Online ISBN: 978-4-431-53977-3
eBook Packages: Springer Book Archive